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Tissue inhibitor of metalloproteinases-1 (TIMP-1) is one of four inhibitors of the matrix metalloproteinases, which are capable of
degrading most components of the extracellular matrix. However, in recent years, TIMP-1 has been recognised as a multifunctional
protein, playing a complex role in cancer. In this regard, several studies have demonstrated an antiapoptotic effect of TIMP-1 in a
number of different cell types. Since chemotherapy works by inducing apoptosis in cancer cells, we raised the hypothesis that TIMP-1
promotes resistance against chemotherapeutic drugs. In order to investigate this hypothesis, we have established TIMP-1 gene-
deficient and TIMP-1 wild-type fibrosarcoma cells from mouse lung tissue. We have characterised these cells with regard to TIMP-1
genotype, TIMP-1 expression, malignant transformation and sensitivity to chemotherapy-induced apoptosis. We show that TIMP-1
gene deficiency increases the response to chemotherapy considerably, confirming that TIMP-1 protects the cells from apoptosis. This
is to our knowledge the first study investigating TIMP-1 and chemotherapy-induced apoptosis employing a powerful model system
comprising TIMP-1 gene-deficient cells and their genetically identical wild-type controls. For future studies, this cell system can be
used to uncover the mechanisms and signalling pathways involved in the TIMP-1-mediated inhibition of apoptosis as well as to
investigate the possibility of using TIMP-1 inhibitors to optimise the effect of conventional chemotherapy.
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The matrix metalloproteinases (MMPs) are a family of proteolytic
enzymes, which are partly responsible for the turnover of the
extracellular matrix in normal physiological conditions of tissue
remodelling as well as in disease conditions such as invasion of
cancer cells (Egeblad and Werb, 2002). Tissue inhibitor of
metalloproteinases-1 (TIMP-1) is a naturally occurring inhibitor
of the MMPs (Brew et al, 2000). It forms 1:1 stoichiometric
complexes with the enzymes, thereby inhibiting the proteolytic
activity of these molecules. Since the proteolytic activity of the
MMPs is believed to facilitate invasion of cancer cells, one would
expect TIMP-1 to inhibit tumour progression. However, a number
of studies have demonstrated that the level of TIMP-1 is increased
in several cancer forms, for example, colorectal and breast cancer
and this increase has often been associated with a poor clinical
outcome of the cancer patients (Ree et al, 1997; Holten-Andersen
et al, 1999, 2000; McCarthy et al, 1999; Schrohl et al, 2004; Yukawa
et al, 2004). This paradoxical finding has been suggested to be the
consequence of distinct tumour-stimulating functions demon-
strated for TIMP-1, for example, stimulation of proliferation
(Hayakawa et al, 1992) and inhibition of apoptosis (Guedez et al,
1998; Li et al, 1999; Murphy et al, 2002; Lee et al, 2003; Liu et al,
2003, 2005; Boulday et al, 2004; Murphy et al, 2004).
The antiapoptotic effect of TIMP-1 induced by various apoptotic
agents has been demonstrated in several different cell types such as
human breast epithelial cells (Li et al, 1999; Liu et al, 2003, 2005),
human breast carcinoma cells (Lee et al, 2003), human endothelial
cells (Boulday et al, 2004), hepatic stellate cells (Murphy et al,
2002, 2004) and Burkitt’s lymphoma cells (Guedez et al, 1998). Of
these studies, only Li et al (1999) investigated the association
between TIMP-1 level and cell survival following treatment with
chemotherapy (adriamycin). However, a specific event of apopto-
sis was not confirmed in this survival experiment. In support of an
antiapoptotic function of TIMP-1, our laboratory has recently
shown that in patients with metastatic breast cancer, the response
to chemotherapy was 0% in patients with primary tumours
containing high levels of TIMP-1, while being 45% in patients with
tumours containing low levels of TIMP-1 supporting a protective
role of TIMP-1 to chemotherapy-induced apoptosis (Wu ¨rtz et al,
2005). Similar results have also been demonstrated for metastatic
colorectal cancer (Sørensen et al, 2006).
Taken together, this raises the hypothesis that TIMP-1 protects
cells against chemotherapeutic treatment by inhibiting apoptosis.
In order to investigate this hypothesis, we have established TIMP-1
gene deficient and TIMP-1 wild-type fibrosarcoma cell lines from
lung tissue originating from littermate mice. We have confirmed
these two different TIMP-1 variants by PCR, RT–PCR, Western
blotting and ELISA. We have demonstrated that the cells display
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simmortalised and clonogenic growth, showing that the cells had
spontaneously transformed to a malignant phenotype. In addition,
we have analysed the sensitivity of the cells to chemotherapy-
induced apoptosis and shown that TIMP-1 gene-deficient cells are
considerably more sensitive to induced apoptosis compared to the
corresponding TIMP-1 wild-type cells. This confirms that TIMP-1
plays a role in inhibition of chemotherapy-induced apoptosis in
the established cell lines. This cell system represents a powerful
tool for further studies of the antiapoptotic role of TIMP-1 in
cancer, especially considering the quality of having a model system
consisting of gene deficient cells and their identically genetic wild-
type control. Furthermore, this cell system can be used to uncover
the mechanisms and signalling pathways involved in the TIMP-1-
mediated inhibition of apoptosis. Evidence from a number of
recent studies suggests that the focal adhesion kinase (FAK)/
phosphatidylinositol-3 kinase (PI-3 kinase)/Akt/Bad/Bcl-XL/Bcl-2
signalling pathway is involved in the TIMP-1-mediated inhibition
of apoptosis (Guedez et al, 1998; Li et al, 1999; Lee et al, 2003; Liu
et al, 2003, 2005; Boulday et al, 2004); however, further studies are
still needed to identify the mechanisms involved.
Importantly, as suggested by the present study, TIMP-1 may be
a new therapeutic target in the optimisation of treatment with
conventional anticancer drugs and future studies using this cell
system offers the opportunity to investigate this hypothesis.
MATERIALS AND METHODS
Compounds
Etoposide (Bristol-Myers Squibb, Denmark), cytosar (Pfizer,
Denmark) and vincristine (Faulding, Denmark) were kindly
provided by Peter Buhl Jensen (Rigshospitalet, Denmark).
Establishment of cell cultures from transgenic mice
TIMP-1 gene-deficient and wild-type mice were kindly provided by
Paul D Soloway, Cornell University (Ithaca, NY, USA). In brief,
TIMP-1 gene-deficient mice were generated by homologous
recombination of a neomycin-containing TIMP-1 insertion vector
in mouse embryonic stem cells. Stem cells were then injected in
blastocysts and transgenic mice were generated by backcrossing
into the BALB/cJ mouse strain. Genotypes of the mice were
determined by PCR on genomic tail DNA (Soloway et al, 1996).
Establishment of cell cultures was performed as described
previously (Rømer et al, 2005). In brief, lungs of TIMP-1 gene-
deficient and wild-type littermate mice (29 weeks old males) were
excised and placed in Petri dishes containing 10ml of medium
(M199, Gibco, Invitrogen A/S, Denmark) supplemented with 30%
foetal calf serum (FCS), penicillin (100units/ml), streptomycin
(100mg/ml) and 1% NaHCO3 (Gibco, Invitrogen A/S, Denmark).
The lungs were cut into small pieces and 3–6 pieces/well were
placed in a six-well plate (Nunc, Denmark) together with a drop of
medium and incubated at 5% CO2 and 371C for 20min to allow the
cells to adhere. After 20min, 1ml of medium was added to
completely cover the tissue. After additional 30min, another 1ml
of medium was added. The medium was renewed every third day.
The wells were inspected regularly during the next 3 weeks and
thereafter the medium added was without penicillin and strepto-
mycin. After 4–5 weeks, the wells with outgrowth of fibroblasts
were harvested and cells from the same mouse were pooled. The
medium was changed to M199 medium with 10% FCS and 0.15%
NaHCO3 (CM). A total of four fibrosarcoma cell lines were
successfully established. These cell lines were named Twt-II and
Twt-III (TIMP-1 wild type) and Tko-II and Tko-III (TIMP-1 gene
deficient), respectively. Within each pair (II and III), the Twt and
Tko cells were derived from littermates in order to assure identical
genetic background. The Twt-II and Tko-II were established 4
months apart from the Twt-III and Tko-III cell lines. The cells were
tested for infectious agents in the Mouse RapidMAP18 panel
(Taconic Europe) all with negative results.
Genotyping
The cells (passages 60–69) were trypsinised, harvested and DNA
was isolated as described previously (Laird et al, 1991). One
microlitre of each DNA sample was transferred to 25ml PCR-
working solution (1 Hot Star Tag Mastermix (Qiagen, Ballerup,
Denmark), MgCl2 (25mM) and 2ml of each primer: forward primer
recognising Twt: 50-CAAGGGGTGCTTAGTTGCTCTGG-30 (exon
3); reverse primer recognising Twt: 50-CACTGCGGTTCTGG
GACTTGTGG-30 (exon 4); forward primer recognising Tko: 50-
GCGAACCCACCTCTCCGATAAGC-30 (neo-cassette) and reverse
primer recognising Tko: 50-CATTCGCCGCCAAGCTCTTCAGC-30
(neo-cassette). The expected size of the Twt-specific PCR product
is approximately 370 base pairs (bp), whereas the Tko-specific
PCR product is approximately 670bp. The reaction conditions
optimised for the two genotype-specific bands were 951C for
15min, followed by 32 cycles of 941C for 1min, 631C for 1min,
721C for 1min and finally 721C for 10min. In each assay, three
controls were included: TIMP-1 þ/0, TIMP-1  /0 (TIMP-1 is
located on the X-chromosome and only male mice were employed
in the experiments; Huebner et al, 1986) and as negative control
H2O. Tissue inhibitor of metalloproteinases-1 þ/0 and TIMP-1
 /0 control samples were obtained by enzymatic digestion of tail
tissue from TIMP-1 wild-type and TIMP-1 gene-deficient mice,
respectively. The PCR products were run on a 2% agarose gel
(Fermentas, Helsingborg, Sweden), stained with ethidium bromide
and visualised by UV light.
RT–PCR
RNA was extracted from the cells (passages 72–78) using an SV
Total RNA isolation kit (Promega, Manheim, Germany). The cells
were grown in 10cm culture dishes to a confluence of 90% and
lysed in 500ml lysis buffer. RNA from 175ml of the lysed cells was
extracted following the manufacturer’s instructions. DNase treat-
ment was included in the protocol to avoid genomic DNA
contamination of the RNA. Concentration of the RNA was
estimated by measuring OD260. Two micrograms of RNA was
reverse transcribed to cDNA in 20ml RT buffer (Fermentas)
containing 1mM dNTPs, 20U RiboLock RNase inhibitor, 0.5mg
oligo(dT)primer, 0.2mg random hexamer primer and 40U
M-MuLV Reverse Transcriptase. Samples were incubated at 251C
for 10min, followed by 421C for 1h. The reaction was terminated
by incubation at 951C for 5min followed by cooling on ice. To
ensure that RNA extractions and RT reactions were successful, PCR
using intron-spanning b-actin primers was performed on all cDNA
samples (forward primer: 50-CGTGGGCCGCCCTAGGCACCA-30
and reverse primer: 50-TTGGCCTTAGGGTTCAGGGGGG-30). The
expected size of the b- actin PCR product is 242bp. To test for
expression of TIMP-1 mRNA from Twt and Tko cells, PCR using
intron-spanning TIMP-1-specific primers was carried out on cell
cDNA (forward primer: 50-GTGGGAAATGCCGCAGATATC-30 and
reverse primer: 50-GACCTGATCCGTCCACAAAC-30). The ex-
pected size of this PCR product is 299bp. PCR was performed in
25ml reactions consisting of 1 Hot Star Taq Mastermix, 1mM of
each gene-specific primer and 1ml cDNA. Reaction conditions
were 951C for 15min followed by 40 cycles of 941C for 1min, 601C
for 30s and 721C for 1min. PCR products were run on a 1.5%
agarose gel (Fermentas), stained with ethidium bromide and
visualised by UV light.
Western blotting
Cells were seeded in 10cm Petri dishes in CM. When about 90%
confluent, the cells were harvested by scraping and resuspended in
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s100ml lysis buffer (0.5% Triton X-100, 25mM Hepes1, 5mM MgCl2,
1m M EGTA, milliQ H2O) containing four protease inhibitors
(Aprotinin, Leupeptin, Pepstatin A and Pefa Block in a final
concentration of 1mg/ml). The protein concentration in each
sample was determined by protein BCA Protein Assay kit (Pierce,
Rockford, IL, USA). Proteins were separated by sodium dodecyl
sulphate (SDS)–gel electrophoresis using a 12% polyacrylamide
gel and blotted on nitrocellulose paper. The blot was blocked in
washing buffer (phosphate-buffered saline (PBS)þ0.1% Tween
20) containing 5% dry milk and incubated with the rat-IgG
antibody to murine TIMP-1 (R&D Systems, UK, 3mg/ml in
washing buffer containing 1% dry milk) or the goat-IgG antibody
to murine p53 (R&D Systems, diluted 1:2000 in washing buffer
containing 1% dry milk) or rat-IgG antibody to murine p19
Arf
(Upstate, Charlottesville, USA, diluted 1:100 in washing buffer
containing 1% dry milk) for TIMP-1, p53 and p19
Arf detection,
respectively. Subsequently, the blot was washed 3 10min in
washing buffer followed by incubation with the appropriate
horseradish peroxidase-conjugated secondary antibody (rabbit-
IgG to rat-IgG diluted 1:1000 or rabbit-IgG to goat-IgG diluted
1:10000 or rabbit-IgG to rat-IgG diluted 1:2000 (DAKO, Den-
mark), respectively). Following 3 10min washes in washing
buffer, the blot was developed by the ECL detection system
(Amersham Bioscience, UK) according to the manufacturer’s
instructions. In order to obtain a loading control, the blot was
stripped and re-probed with a primary monoclonal antibody
recognising glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
(Biogenesis, UK, diluted 1:80000 in washing buffer containing 1%
dry milk). Subsequently, the blot was washed 3 10min in
washing buffer and incubated with a polyclonal horseradish
peroxidase-conjugated goat-IgG to mouse-IgG (DAKO, Denmark,
diluted 1:100000 in washing buffer containing 1% dry milk) for
1h. Finally, the blot was washed 3 10min in washing buffer and
developed as described above. Details regarding cells are indicated
in the figure legends.
Murine TIMP-1 ELISA
Cells (2500cells/well, passages 55–56) were seeded in 96-well
microtitre plates in triplicate in 100ml CM. After 24h, the CM was
replaced with 150ml new CM. After another 24h, the CM was
collected, centrifuged for 5min at 300g and the supernatant
transferred to Eppendorf tubes and stored at  201C. The amount
of TIMP-1 secreted in the CM was measured using Quantikine
Mouse TIMP-1 Immunoassay (R&D Systems, UK) according to the
manufacturer’s instructions.
Clonogenic assay
Clonogenic assay was performed as described previously (Jensen
et al, 1993). In brief, cells (passages 27–35) were suspended in CM
supplemented with penicillin (50U/ml) and streptomycin (50mg/
ml). A volume of 350ml cell suspension was mixed with a mixture
of agar and medium. One microlitre of the cell-containing agar was
then plated in triplicate in Petri dishes over a layer of sheep red
blood cells. When the agar had solidified, 1ml of media were
added on top. Cells were grown in a CO2 incubator (7.5% CO2)a t
371C and 100% humidity. Following 3 weeks of incubation,
colonies (464 cells) were counted using the software Sorcerer
(Perceptive Instruments, Suffolk, UK).
Flow cytometrical analysis
DNA ploidy of early (passages 29–38), middle (passages 45–48)
and late passages (passages 62–71) was determined for each cell
line by flow cytometrical analysis as described previously
(Vindeløv and Christensen, 1990; Rømer et al, 2005). All
measurements were related to the DNA index of normal diploid
mouse cells.
Cell death assays
Lactate dehydrogenase (LDH) release assay To investigate the
response to chemotherapy in the cell lines, cytotoxicity was
determined following treatment with chemotherapeutic drugs.
During cell culture conditions, cells that have been given an
apoptotic stimulus will initially die by apoptosis and later turn into
secondary necrosis due to the lack of phagocytosis. Cytotoxicity or
cell lysis can be measured by the release of LDH in the culture
supernatant. To measure the LDH release, the Cytotoxicity
Detection Kit (Roche, Hvidovre, Denmark) was employed. The
cells (passages 39–87) were seeded in 96-well microtitre plates
(3000cells/well). After 24h, the cells were treated with the
chemotherapeutic drug. After 48h (etoposide) or 35h (cytosar
and vincristine) incubation, 50ml (out of 200ml) of culture
supernatant was transferred to a new 96-well microtitre plate
and mixed with 50ml of substrate mix. The remaining culture
supernatant was discarded and the residual intact adherent cells
were lysed by the addition of 200ml lysis buffer (1% Triton X-100
in CM). Following lysis for 30min at 5% CO2 and 371C, 50ml of the
lysate was transferred to a new 96-well microtitre plate and mixed
with 50ml of substrate mix. Both the cell culture supernatants and
the lysates were incubated with substrate mix for 10min at room
temperature protected from light. The absorbance was measured
in a spectrophotometer at l1¼570nm and reference l2¼630nm.
The amount of released LDH in per cent was related to the total
amount as follows:
Cytotoxicityð%LDHreleaseÞ¼
ðLDHsupernatant=TotalLDHðLDHsupernatantþLDHlysateÞÞ 100%:
Apoptosis assay To confirm that the cell death observed in the
LDH assay was apoptotic, the presence of DNA–histone complexes
in the cytoplasm following the apoptotic stimuli was measured. For
this purpose, the Cell Death Detection ELISA Kit (Roche) was
employed. The cells (passages 39–87) were seeded in a 96-well
microtitre plates (3000cells/well). After 24h, the cells were treated
with the chemotherapeutic drug for 48h (etoposide) or 35h
(cytosar and vincristine) and the level of apoptosis was measured
according to the manufacturer’s instructions. The degree of
apoptosis (DNA fragmentation) was calculated as follows:
absorbance of sample (dying and dead cells)/absorbance of
corresponding control (viable cells).
Cell proliferation assay
Cell proliferation was estimated using the CyQuant
s Cell
Proliferation Assay Kit (Molecular Probes Inc., Eugene, OR,
USA/Invitrogen, Denmark). Cells (500 cells/well, passages 49–51
and passages 81–86) were seeded in 96-well microtitre plates and
harvested daily over a 5- or 6-day period. Proliferation rates were
analysed by spectrophotometrical measurements of the DNA and
RNA content at 480nm excitation and 520nm emission according
to manufacturer’s instructions.
RESULTS
TIMP-1 genotype and TIMP-1 expression
In order to confirm the absence or presence of TIMP-1 in the
TIMP-1 gene-deficient and the TIMP-1 wild-type cells, respec-
tively, genotyping, RT–PCR, Western blotting and ELISA were
performed (Figure 1). Genotypes of the TIMP-1 wild-type and
TIMP-1 gene-deficient cells were determined by PCR (Figure 1A).
As expected, the wild-type control (TIMP-1 þ/0) gave rise to a
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TIMP-1 gene (Figure 1A, lane 5). Bands of the same sizes appeared
when PCR was performed on lysates from the Twt-II and Twt-III
cell lines, thereby confirming that both of these cell lines exhibit
the wild-type TIMP-1 gene (Figure 1A, lanes 1 and 3). In contrast,
the PCR of the TIMP-1 gene-deficient control (TIMP-1  /0)
resulted in a PCR product of approximately 670bp, reflecting
disruption of exon 4 in the TIMP-1 gene by insertion of a neo-
cassette (Figure 1A, lane 6). The band of 670bp was also present in
the Tko-II and Tko-III cell lines confirming the gene-deficient
status of these cells. To ensure that the TIMP-1 gene is only
transcribed in the TIMP-1 wild-type cells and not in the TIMP-1
gene-deficient cells, RT–PCR assay of cell lysates from the Twt-II,
Twt-III as well as the Tko-II and Tko-III cell lines was performed
(Figure 1B). As Figure 1B shows, only the wild-type cells gave rise
to a TIMP-1 mRNA transcript (compare lanes 1 and 2 with lanes 3
and 4). Using b-actin primers resulted in a PCR product of the
expected size in all samples, confirming the presence of cDNA
(Figure 1B). To investigate whether the expression of TIMP-1
observed in the wild-type, but not in the gene-deficient cells also
applied to TIMP-1 protein, Western blotting was performed
(Figure 1C). As seen in the figure, only the Twt cells expressed
the TIMP-1 protein (lanes 2 and 4), whereas the Tko cells did not
(lanes 1 and 3). In addition, it can be seen that the Twt-III has
an overall increased level of TIMP-1 expression compared to the
Twt-II cells. Likewise, ELISA measurements showed a considerably
higher amount of TIMP-1 protein in CM from Twt-III cells
(B8.6ng/ml)) compared to Twt-II cells (B2.2ng/ml), and no
TIMP-1 was detected in either of the TIMP-1 gene-deficient cell
lines.
Transformation of the cells
The cells were analysed to establish whether they had sponta-
neously transformed to a malignant phenotype. All four cell lines
displayed immortalised growth since they survived in culture at
least to passage 120. More importantly, the clonogenic assay
demonstrated that all cell lines were able form colonies in soft agar
(data not shown).
Loss of euploidy is a characteristic of the transformation process
and therefore we investigated DNA ploidy of the cells (Figure 2A
and B). This analysis showed that both Twt-II and Tko-II cells were
aneuploid in all the investigated passages according to their DNA
indices of approximately 1.5. Both cell lines had subpopulations in
different passages (Figure 2A). Likewise, the Tko-III cells were
aneuploid, having a DNA index of approximately 1.6 with a single
subpopulation. In contrast, the Twt-III cells were diploid with a
DNA index of 1 in all passages tested (Figure 2B). Disruption of the
p53 signalling pathway is also a frequent event in the transforma-
tion process. This typically occurs by an inactivation mutation in
the p53 gene or inactivation of the tumour suppressor p19
Arf,a
positive regulator of the p53 gene. Inactivation of p53 directly leads
to an increase in the expression level of the protein (Soussi and
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Figure 1 Confirming the absence or presence of TIMP-1 in the gene-
deficient and wild-type fibrosarcoma cell lines respectively. (A) Genotyping.
Lane 1: Twt-II in passage 60; lane 2: Tko-II in passage 60; lane 3: Twt-III in
passage 65; lane 4: Tko-III in passage 65; lane 5: þ/0 TIMP-1 control; and
lane 6:  /0 Timp-1 control. The PCR was performed on lysate from the
cells, each sample and each control with both sets of primers. (B)R T –
PCR. Lane 1: Twt-II in passage 73; lane 2: Twt-III in passage 78; lane 3: Tko-II
in passage 72; and lane 4: Tko-III in passage 78. The RT–PCR has been run
on lysate from the cells, each sample with intron-spanning b-actin primers
and with intron-spanning TIMP-1-specific primers. (C) Western blotting.
Lane 1: Tko-II in passage 74; lane 2: Twt-II in passage 68; lane 3: Tko-III in
passage 74; and lane 4: Twt-III in passage 70. In each lane, equal amounts of
protein (60mg protein) are loaded. The presence of two bands may reflect
two different glycosylation products of TIMP-1.
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Figure 2 Transformation of the cell lines. (A, B) DNA ploidy analysis of
Twt-II and Tko-II and Twt-III and Tko-III, respectively, in early, middle and
late passages. A DNA index of 1 represents normal diploid mouse DNA
content. (C) Western blot of p53 expression in the fibrosarcoma cells.
Lane 1: Tko-II in passage 11; lane 2: Tko-II in passage 69; lane 3: Twt-II in
passage 14; lane 4: Twt-II in passage 68; lane 5: Tko-III in passage 12; lane 6:
Tko-III in passage 74; lane 7: Twt-III in passage 10; and lane 8: Twt-III in
passage 70. In each lane equal amounts of protein (40mg) are loaded.
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sBe ´roud, 2001). Western blotting showed a pronounced increase in
the expression level of p53 in late passages (4passage 68)
compared to early passages (opassage 14) of Twt-II, Tko-II and
Tko-III cells (Figure 2C). In contrast, the immunoblot analysis of
the Twt-III cells revealed no detectable levels of p53 in either early
or late passages. Thus, this further supports that the Twt-II, Tko-II
and Tko-III cells have been malignantly transformed. The fact that
there was no indication of inactivation of the p53 pathway in the
Twt-III cells and that the cells were diploid implies that a different
transformation process had taken place in this cell line. To analyse
this further, we investigated the level of the tumour suppressor
p19
Arf. As determined by Western blotting, there was no
expression of p19
Arf in late passages of Twt-III cells, indicating
that an indirect disruption of the p53 signalling pathway had taken
place, thereby supporting that these cells had been malignantly
transformed, although through a different process compared to the
other cell lines (data not shown).
TIMP-1 gene deficiency confers increased sensitivity to
chemotherapeutic drugs
TIMP-1 has been demonstrated to inhibit apoptosis induced by
various stimuli in several different types of cells (Guedez et al,
1998; Li et al, 1999; Murphy et al, 2002; Lee et al, 2003; Liu et al,
2003, 2005; Boulday et al, 2004; Murphy et al, 2004). In order to
investigate whether TIMP-1 inhibits chemotherapy-induced apop-
tosis, we tested the sensitivity of the TIMP-1 wild-type and the
TIMP-1 gene-deficient cells to treatment with three different
chemotherapeutic drugs and the cytotoxicity was measured by
LDH release assay (Figure 3). In Figure 3A, the results from
treatment of the Twt-II and Tko-II cell lines with the drug
etoposide are shown. As seen in the figure, both cell lines displayed
a dose-dependent response to the treatment; however, the TIMP-1
gene-deficient cells were considerably more sensitive to the
treatment compared to the wild-type cells. To confirm that
the cell death induced by etoposide was apoptotic, we determined
the level of DNA–histone complexes in the cytoplasm following
drug treatment. As is evident from Figure 3B, the cell death
induced by etoposide was indeed apoptotic. The experiments with
etoposide were also conducted with Twt-III and Tko-III with the
same results (data not shown) showing that the TIMP-1-mediated
protection was not dependent on the transformation process. We
also tested the effect of the two chemotherapeutic drugs, cytosar
and vincristine, on the Twt-II and Tko-II cell lines. The results
from the LDH release assay as well as the apoptosis assay are
shown in Figure 3C–F. As was the case concerning etoposide, the
Tko-II cells were considerably more sensitive to the drugs tested
compared to the Twt-II cells as determined by LDH release assay
(Figure 3C and E). In addition, the apoptosis assay confirmed that
the enhanced cell death observed in the Tko-II cells was a result of
increased apoptosis (Figure 3D and F). Together, these results
demonstrate that TIMP-1 deficiency increases the cellular response
to chemotherapy-induced apoptosis.
Similar growth rates of the TIMP-1 gene-deficient and
wild-type cells
In general, chemotherapeutic drugs induce apoptosis in cancer
cells by disturbance of cell division through damaging of the DNA.
Therefore, rapidly dividing cells are affected more by chemother-
apy than normally dividing cells. To ensure that the differential
response to chemotherapy observed in the cell lines is not the
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Figure 3 Sensitivity to chemotherapeutic drugs. Twt-II and Tko-II cells
were treated with etoposide (A, B) for 48h or cytosar (C, D)o r
vincristine (E, F) for 35h. Induced cell death (A, C, E) and induced
apoptosis (B, D, F) are depicted for all three drugs. The experiments were
repeated more than three times through passages 39–87 with same
results. This figure is representative of all experiments performed. Values
represent means of triplet determination7s.d.
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Figure 4 Proliferation. Growth rates of Twt-II and Tko-II were
investigated by a proliferation assay. Fluorescence reflects the DNA
content. (A) Twt-II and Tko-II in passages 49–51. (B) Twt-II and Tko-II in
passages 81–82.
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of the cells using a cell proliferation assay (Figure 4). In passages
49–51, the doubling time for Twt-II was 1.96 days and for Tko-II
1.86 days (Figure 4A), and in passages 81–86, the doubling times
was 1.20 and 0.94 days (Figure 4B), respectively, confirming
similar proliferation rates of the TIMP-1 gene-deficient and wild-
type cells. Thus, the difference in sensitivity to induced apoptosis
cannot be ascribed to a difference in growth rates. Similar growth
rates were also found for Twt-III (passages 49–51: 1.28 days;
passage 81–86: 1.21 days) and Tko-III (passages 49–51: 1.94;
passage 81–86: 1.41 days).
DISCUSSION
It is well established that TIMP-1 is able to inhibit apoptosis
induced by various apoptotic stimuli in a number of different cell
types. A single study has suggested that TIMP-1 enhances survival
during chemotherapeutic treatment (Li et al, 1999). In addition,
recent clinical studies demonstrated a significant association
between high tumour tissue levels of TIMP-1 and no objective
responses to the most frequently used chemotherapeutic drugs for
patients with metastatic breast cancer and colorectal cancer,
indicating that TIMP-1 also protects against chemotherapy-
induced apoptosis in vivo (Wu ¨rtz et al, 2005; Sørensen et al, 2006).
In an attempt to obtain a system, which can be used for further
investigations of the protective function of TIMP-1 against
chemotherapy-induced apoptosis, we have established TIMP-1
wild-type and TIMP-1 gene-deficient fibrosarcoma cell lines from
lung tissue originating from littermate mice. We have charac-
terised these cells and confirmed the two different TIMP-1 variants
by PCR, RT–PCR, Western blotting and ELISA. Moreover, we have
assured that the cells have been malignantly transformed by
demonstration of immortalised and clonogenic growth as well as
aneuploidy and/or disruption of the p53 signalling pathway. It
should be emphasised that this new well-characterised cell system
has the strength of exhibiting two pairs of cell lines sharing, except
from TIMP-1, identical genetic backgrounds, making it possible to
investigate the isolated function of TIMP-1.
To investigate whether TIMP-1 could play a role in inhibition of
chemotherapy-induced apoptosis in our cell system, we tested the
response of the cells to apoptosis induced by three different
chemotherapeutic drugs. We showed that the TIMP-1 gene-
deficient fibrosarcoma cells were considerably more sensitive to
the chemotherapeutic drugs tested, compared to the correspond-
ing TIMP-1 wild-type cells, confirming that TIMP-1 protects
against chemotherapy in our model system. Interestingly, the
higher level of TIMP-1 expression observed in the Twt-III cell line
compared to the Twt-II cell line is not associated with increasing
protection against apoptosis, suggesting that both wild-type cell
lines have reached a saturation level of TIMP-1 concerning the
protection against apoptosis (data not shown). Furthermore, the
protection seems independent of the mechanism by which
apoptosis was induced, since TIMP-1 protected the cells from
apoptosis induced by three different drugs (etoposide, cytosar and
vincristine) working through different DNA-damaging mechan-
isms (inhibitor of topoisomerase II, inhibitor of DNA repair and
DNA polymerase and an antimicrotubule agent, respectively)
(Holland et al, 2000). As the differential response to chemotherapy
could be the result of different growth rates in the cell lines, we
analysed the proliferation rates of the cells. We found that the
TIMP-1 wild-type and the TIMP- 1 gene-deficient cells had similar
growth rates, confirming that the difference in response to
apoptosis-inducing drugs was not the result of a difference in
growth, but was coursed by inhibition of apoptosis in the wild-type
cells. Interestingly, a previous study completed in our laboratory
has revealed a similar association between plasminogen activator
inhibitor-1 (PAI-1) gene deficiency and increased sensitivity to
chemotherapy-induced apoptosis (Lademann et al, 2005; Rømer
et al, 2005), suggesting an overlapping role of TIMP-1 and PAI-1.
Therefore, we have established fibrosarcoma cells lines simulta-
neously deficient of the TIMP-1 and the PAI-1 genes, which can be
used to investigate possible common characteristics of these two
inhibitors (currently under investigation).
In summary, the cell systems established in this study have been
thoroughly characterised with regard to TIMP-1 genotype, TIMP-1
expression, malignant transformation and response to chemo-
therapy. Our studies demonstrated that TIMP-1 deficiency confers
a pronounced increase in sensitivity to apoptosis induced by
chemotherapy, confirming that TIMP-1 plays a role in inhibition
of apoptosis. Addition of exogenous TIMP-1 or reintroduction of
the TIMP-1 gene in the gene-deficient cell lines, as well as
inhibition of TIMP-1 expression in the wild-type cell lines, would
further validate the specific antiapoptotic function of TIMP-1.
The established cell lines represent very important tools for
future investigations of the antiapoptotic function of TIMP-1,
especially considering the quality of having a model system, which
includes the gene-deficient cells and their identical genetic wild-
type controls, together with the possibility of conducting in vivo
experiments. These include studying the effect of chemotherapeu-
tic drugs on tumours induced by inoculation of our cells in the
TIMP-1 gene-deficient and wild-type BALB/cJ mouse strain.
Finally, this model system can also be employed in the search for
a putative TIMP-1 binding protein and the investigations of
signalling pathways in which TIMP-1 may be involved. Obvious
candidate molecules to be investigated are the molecules included
in the survival pathway such as FAK, PI-3 kinase, Akt and Bcl-2
family members, previously shown to be regulated by TIMP-1.
Importantly, the experiments performed suggest that TIMP-1
inhibitors could represent a novel treatment as a chemosensitising
approach given before conventional therapy and the model
system presented here offers the opportunity to investigate this
hypothesis.
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